TWI485161B - 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 - Google Patents

抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 Download PDF

Info

Publication number
TWI485161B
TWI485161B TW102107344A TW102107344A TWI485161B TW I485161 B TWI485161 B TW I485161B TW 102107344 A TW102107344 A TW 102107344A TW 102107344 A TW102107344 A TW 102107344A TW I485161 B TWI485161 B TW I485161B
Authority
TW
Taiwan
Prior art keywords
epcam
antibody
cells
cell
binding fragment
Prior art date
Application number
TW102107344A
Other languages
English (en)
Chinese (zh)
Other versions
TW201350507A (zh
Inventor
吳漢忠
廖美英
林政緯
Original Assignee
中央研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院 filed Critical 中央研究院
Publication of TW201350507A publication Critical patent/TW201350507A/zh
Application granted granted Critical
Publication of TWI485161B publication Critical patent/TWI485161B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
TW102107344A 2012-03-02 2013-03-01 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法 TWI485161B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261606220P 2012-03-02 2012-03-02

Publications (2)

Publication Number Publication Date
TW201350507A TW201350507A (zh) 2013-12-16
TWI485161B true TWI485161B (zh) 2015-05-21

Family

ID=49083343

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102107344A TWI485161B (zh) 2012-03-02 2013-03-01 抗上皮細胞黏著分子（ＥｐＣＡＭ）抗體及其使用方法

Country Status (6)

Country Link
US (1) US9187558B2 (enExample)
EP (1) EP2819695B1 (enExample)
JP (1) JP6163502B2 (enExample)
CN (1) CN104168916B (enExample)
TW (1) TWI485161B (enExample)
WO (1) WO2013131001A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110763842A (zh) 2011-06-29 2020-02-07 中央研究院 使用表面涂层对生物物质的捕获、纯化和释放
CN106662514A (zh) 2014-04-01 2017-05-10 中央研究院 用于癌症诊断及预后的方法和系统
EP3328897A1 (en) * 2015-07-31 2018-06-06 Sutro Biopharma, Inc. ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EPCAM ANTIBODIES
EP3903818A1 (en) * 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
JP6433951B2 (ja) * 2016-08-09 2018-12-05 東芝デジタルソリューションズ株式会社 ネットワーク監視装置およびプログラム
US10787499B2 (en) 2017-02-13 2020-09-29 Regents Of The University Of Minnesota EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020051141A1 (en) * 2018-09-04 2020-03-12 Academia Sinica A medium composition and method for culturing mesenchymal stem cells
CN113874400B (zh) * 2019-03-11 2025-02-07 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
EP3983446A4 (en) * 2019-06-11 2023-04-19 BioAtla, Inc. CONDITIONALLY ACTIVE ANTI-EPCAM ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND THEIR USE
JP7696343B2 (ja) * 2019-11-14 2025-06-20 アカデミア シニカ がん治療における抗ＥｐＣＡＭ抗体の使用
CN110950959B (zh) * 2020-02-25 2020-07-03 和铂医药(上海)有限责任公司 靶向EpCAM的抗体及其制备和应用
CN112094350B (zh) * 2020-06-01 2024-01-05 普众发现医药科技(上海)有限公司 可应用于肿瘤细胞捕获的小鼠抗细胞表面糖蛋白cd326的单克隆抗体
JP7570653B2 (ja) * 2020-08-19 2024-10-22 ▲蘇▼州易慕峰生物科技有限公司 ヒト化抗体、キメラ抗原受容体、核酸、ベクター、細胞及び応用
CA3205465A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Epcam binding molecules and uses thereof
TWI754504B (zh) * 2020-12-25 2022-02-01 龍華科技大學 棉花棒棒體之膠體檢測系統及其檢測方法
CA3221800A1 (en) * 2021-06-25 2022-12-29 Han-Chung Wu Combined cancer therapy with an epithelial cell adhesion molecule (epcam) inhibitor and a wnt inhibitor
TW202317189A (zh) * 2021-06-25 2023-05-01 中央研究院 上皮細胞粘附分子(epcam)抑制劑及肝臟生長因子受體(hgfr)抑制劑的結合癌症治療
JP7794605B2 (ja) * 2021-11-05 2026-01-06 シスメックス株式会社 抗体の製造方法及び抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092491A1 (en) * 2007-04-04 2010-04-15 Anna Anastasi Anti-epcam antibody and uses thereof
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902553T2 (xx) * 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
CA2396029A1 (en) * 1999-12-27 2001-07-05 Crucell Holland B.V. Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7696320B2 (en) * 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
WO2004106917A2 (de) * 2003-06-02 2004-12-09 Igeneon Krebs-Immuntherapie Forschungs- Und Entwicklungs-Ag Verfahren zur selektion von epitopen zur immuntherapie
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
EP2004695A2 (en) * 2005-07-08 2008-12-24 Xencor, Inc. Optimized anti-ep-cam antibodies
US7521195B1 (en) * 2005-07-21 2009-04-21 Celera Corporation Lung disease targets and uses thereof
JP2011193728A (ja) * 2008-07-17 2011-10-06 Murata Mfg Co Ltd ＥｐＣＡＭに結合能を有するペプチド
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
JP6048660B2 (ja) * 2009-09-21 2016-12-21 ランジュ ラルハン 甲状腺癌を診断および処置するための方法および組成物
EP2567235B1 (en) * 2010-05-04 2017-08-30 Paul Walfish Method for the diagnosis of epithelial cancers by the detection of epicd polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092491A1 (en) * 2007-04-04 2010-04-15 Anna Anastasi Anti-epcam antibody and uses thereof
TW201125583A (en) * 2009-12-23 2011-08-01 Bioalliance Cv Anti-EpCAM antibodies that induce apoptosis of cancer cells and methods using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
P Ruf et al, Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer, British Journal of Cancer (2007) 97, 315 – 321 *

Also Published As

Publication number Publication date
EP2819695A1 (en) 2015-01-07
JP2015517982A (ja) 2015-06-25
CN104168916B (zh) 2017-07-04
JP6163502B2 (ja) 2017-07-12
EP2819695B1 (en) 2018-06-27
US20150017230A1 (en) 2015-01-15
CN104168916A (zh) 2014-11-26
US9187558B2 (en) 2015-11-17
EP2819695A4 (en) 2016-01-20
TW201350507A (zh) 2013-12-16
WO2013131001A1 (en) 2013-09-06

Similar Documents

Publication Publication Date Title
JP6163502B2 (ja) 抗上皮細胞接着分子（ＥｐＣＡＭ）抗体及びその使用方法
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
US9062100B2 (en) Anti-human TROP-2 antibody having anti-tumor activity in vivo
KR102159773B1 (ko) 글리피칸-3에 대한 고친화력 단클론 항체 및 이의 용도
EP2096122B1 (en) Anti-human dlk-1 antibody showing anti-tumor activity in vivo
US8017118B2 (en) Anti-hDlk-1 antibody having an antitumor activity in vivo
JPWO2014054820A1 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
US10246517B2 (en) Antibody binding to carbonic anhydrase and use thereof
HK1198042A (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo
NZ623464B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
HK1198042B (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo
NZ716839B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
NZ716839A (en) Anti-human trop-2 antibody having an antitumor activity in vivo